What is the recommended treatment protocol for Emsam (selegiline) transdermal for major depressive disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Emsam (Selegiline Transdermal System) Treatment Protocol for Major Depressive Disorder

Recommended Dosing Strategy

Start Emsam at 6 mg/24 hours applied once daily as the initial dose for major depressive disorder, which is effective and does not require dietary tyramine restrictions at this dose. 1, 2, 3

Dose Titration

  • Initial dose: 6 mg/24 hours patch applied once daily 1, 4, 3
  • Dose escalation: May increase to 9 mg/24 hours or 12 mg/24 hours if inadequate response after 6-8 weeks, though dietary tyramine restrictions become necessary at these higher doses 5, 2, 4
  • The 6 mg/24 hours dose provides sufficient brain MAO inhibition for antidepressant effects while avoiding significant gastrointestinal MAO-A inhibition, eliminating the "cheese reaction" risk 1, 3

Critical Dietary Restrictions

At 6 mg/24 hours, no dietary tyramine restrictions are required. 1, 2, 3

At 9 mg/24 hours or 12 mg/24 hours, dietary tyramine restriction is mandatory to prevent hypertensive crisis, though current data on this requirement remains insufficient 5, 2

Monitoring Protocol

Begin monitoring within 1-2 weeks of initiation, focusing on suicidal ideation, agitation, irritability, and unusual behavioral changes. 6

  • Monitor for treatment response using validated tools (PHQ-9 or HAM-D) at regular intervals 6, 7
  • Assess for adequate response at 6-8 weeks; if inadequate, modify treatment 6
  • The acute treatment phase lasts 6-12 weeks 6, 7

Treatment Duration

Continue treatment for 4-9 months after achieving satisfactory response in first-episode depression. 6

For patients with 2 or more depressive episodes, consider years to lifelong maintenance therapy. 6

  • A 52-week prevention study demonstrated significant benefits for continuation treatment 2

Absolute Contraindications and Drug Interactions

Do not combine Emsam with the following medications due to risk of severe CNS toxicity, serotonin syndrome, or death: 5, 2

  • Selective serotonin reuptake inhibitors (SSRIs): fluoxetine, sertraline, paroxetine 5
  • Serotonin-norepinephrine reuptake inhibitors (SNRIs) 2
  • Tricyclic antidepressants: amitriptyline, protriptyline - severe CNS toxicity with hyperpyrexia and death reported 5
  • Meperidine and multiple analgesics 2
  • Carbamazepine (significantly increases selegiline levels) 2
  • Indirect sympathomimetics 2

Washout Periods

When discontinuing contraindicated medications before starting Emsam: Wait 1 week (4-5 half-lives) for most medications 2

When discontinuing fluoxetine before starting Emsam: Wait at least 5 weeks due to long half-life of fluoxetine and its active metabolite 5

When discontinuing Emsam before starting contraindicated medications: Wait 2 weeks 2

When discontinuing Emsam before starting tricyclic antidepressants or SSRIs: Wait at least 14 days 5

Common Adverse Effects

The most frequently reported side effects include 2, 4:

  • Application site reactions (most common) 2
  • Insomnia 2
  • Orthostatic hypotension (slightly higher rate than placebo) 2
  • Notably absent: No significant weight gain or sexual dysfunction 2

Safety Profile

No cases of hypertensive crisis were reported in clinical trials at any dose (6,9, or 12 mg/24 hours), even without dietary restrictions. 2, 3

Tyramine challenge studies demonstrated a comfortable safety margin at 6 mg/24 hours 2

Optimal Patient Selection

Emsam is particularly appropriate for patients who 1, 8:

  • Cannot tolerate oral antidepressants
  • Have poor medication adherence
  • Present with atypical depressive symptoms
  • Have failed other antidepressants
  • Have anxious depression 8
  • Have swallowing difficulties 8

Clinical Pitfalls to Avoid

Never exceed 10 mg/day without dietary restrictions - selectivity for MAO-B diminishes with increasing doses, and non-selective MAO inhibition occurs around 30-40 mg/day 5

Do not assume all doses are dietary restriction-free - only the 6 mg/24 hours dose has established safety without tyramine restrictions 1, 2

Do not overlook the washout period requirements - inadequate washout periods before or after Emsam can result in fatal serotonin syndrome or hypertensive crisis 5, 2

References

Research

Transdermal selegiline for the treatment of major depressive disorder.

Neuropsychiatric disease and treatment, 2007

Research

Seligiline transdermal system in depression.

Expert opinion on pharmacotherapy, 2007

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment Options for Anxiety and Major Depressive Disorder (MDD)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

EMSAM (deprenyl patch): how a promising antidepressant was underutilized.

Neuropsychiatric disease and treatment, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.